MXPA03006989A - Leptina modificada con inmunogenicidad reducida. - Google Patents
Leptina modificada con inmunogenicidad reducida.Info
- Publication number
- MXPA03006989A MXPA03006989A MXPA03006989A MXPA03006989A MXPA03006989A MX PA03006989 A MXPA03006989 A MX PA03006989A MX PA03006989 A MXPA03006989 A MX PA03006989A MX PA03006989 A MXPA03006989 A MX PA03006989A MX PA03006989 A MXPA03006989 A MX PA03006989A
- Authority
- MX
- Mexico
- Prior art keywords
- reduced immunogenicity
- modified leptin
- leptin
- modified
- immunogenicity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/20—Protein or domain folding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Theoretical Computer Science (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Child & Adolescent Psychology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01102618 | 2001-02-06 | ||
EP01103954 | 2001-02-19 | ||
PCT/EP2002/001188 WO2002062833A2 (en) | 2001-02-06 | 2002-02-05 | Modified leptin with reduced immunogenicity |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03006989A true MXPA03006989A (es) | 2003-11-18 |
Family
ID=26076461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03006989A MXPA03006989A (es) | 2001-02-06 | 2002-02-05 | Leptina modificada con inmunogenicidad reducida. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20040072219A1 (es) |
EP (1) | EP1387856A2 (es) |
JP (1) | JP2004532618A (es) |
KR (1) | KR20030074788A (es) |
CN (1) | CN1491232A (es) |
BR (1) | BR0207018A (es) |
CA (1) | CA2437265A1 (es) |
HU (1) | HUP0402071A2 (es) |
MX (1) | MXPA03006989A (es) |
PL (1) | PL362375A1 (es) |
RU (1) | RU2003125638A (es) |
WO (1) | WO2002062833A2 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU756617B2 (en) | 1998-07-28 | 2003-01-16 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Leptin-mediated gene-induction |
DE60112282T2 (de) | 2000-05-22 | 2006-04-20 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Auf rezeptorgrundlage arbeitende screening-verfahren für protein wechselwirkungen |
US7235629B2 (en) | 2000-11-14 | 2007-06-26 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Functional fragment of the leptin receptor |
US7423113B2 (en) | 2004-08-25 | 2008-09-09 | Vib Vzw | Leptin antagonist |
DK1814590T4 (da) | 2004-11-01 | 2014-02-24 | Amylin Pharmaceuticals Llc | Behandling af obesitet og beslægtede sygdomme. |
EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
US7307142B2 (en) * | 2004-11-26 | 2007-12-11 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem | Leptin antagonists |
CA2691539C (en) * | 2007-06-21 | 2014-08-26 | Angelica Therapeutics, Inc. | Modified toxins |
EP3103880A1 (en) * | 2008-02-08 | 2016-12-14 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
EP2252314B1 (en) * | 2008-02-27 | 2014-04-09 | Temple University - Of The Commonwealth System of Higher Education | Leptin agonist and methods of use |
US8470314B2 (en) * | 2008-02-29 | 2013-06-25 | Angelica Therapeutics, Inc. | Modified toxins |
WO2011002673A1 (en) * | 2009-07-01 | 2011-01-06 | Temple University - Of The Commonwealth System Of Higher Education | Leptin agonist and methods of use |
WO2014150600A2 (en) | 2013-03-15 | 2014-09-25 | Angelica Therapeutics, Inc. | Modified toxins |
CN114634552B (zh) * | 2022-04-14 | 2022-12-13 | 中国农业大学 | 一种抗肥胖十三肽及其应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22615A1 (es) * | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
US6225446B1 (en) * | 1995-12-06 | 2001-05-01 | Schering Corporation | Mutational variants of mammalian proteins |
US6025324A (en) * | 1996-05-15 | 2000-02-15 | Hoffmann-La Roche Inc. | Pegylated obese (ob) protein compositions |
AU5802898A (en) * | 1996-12-20 | 1998-07-17 | Eli Lilly And Company | Anti-obesity proteins |
CA2290485C (en) * | 1997-05-21 | 2008-08-05 | Biovation Limited | Method for the production of non-immunogenic proteins |
US6838269B1 (en) * | 1998-04-15 | 2005-01-04 | Genencor International, Inc. | Proteins producing an altered immunogenic response and methods of making and using the same |
US6835550B1 (en) * | 1998-04-15 | 2004-12-28 | Genencor International, Inc. | Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins |
EP1051432B1 (en) * | 1998-12-08 | 2007-01-24 | Biovation Limited | Method for reducing immunogenicity of proteins |
JP2004532617A (ja) * | 2001-02-06 | 2004-10-28 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 低減された免疫原性を有する修飾されたヒト脳由来の好中性因子(bdnf) |
-
2002
- 2002-02-05 MX MXPA03006989A patent/MXPA03006989A/es unknown
- 2002-02-05 CN CNA028046110A patent/CN1491232A/zh active Pending
- 2002-02-05 EP EP02719768A patent/EP1387856A2/en not_active Withdrawn
- 2002-02-05 PL PL36237502A patent/PL362375A1/xx unknown
- 2002-02-05 HU HU0402071A patent/HUP0402071A2/hu unknown
- 2002-02-05 RU RU2003125638/13A patent/RU2003125638A/ru not_active Application Discontinuation
- 2002-02-05 CA CA002437265A patent/CA2437265A1/en not_active Abandoned
- 2002-02-05 WO PCT/EP2002/001188 patent/WO2002062833A2/en not_active Application Discontinuation
- 2002-02-05 KR KR10-2003-7010323A patent/KR20030074788A/ko not_active Application Discontinuation
- 2002-02-05 BR BR0207018-9A patent/BR0207018A/pt not_active IP Right Cessation
- 2002-02-05 US US10/467,114 patent/US20040072219A1/en not_active Abandoned
- 2002-02-05 JP JP2002563185A patent/JP2004532618A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
PL362375A1 (en) | 2004-10-18 |
WO2002062833A3 (en) | 2003-10-30 |
KR20030074788A (ko) | 2003-09-19 |
US20040072219A1 (en) | 2004-04-15 |
RU2003125638A (ru) | 2005-03-10 |
CA2437265A1 (en) | 2002-08-15 |
JP2004532618A (ja) | 2004-10-28 |
EP1387856A2 (en) | 2004-02-11 |
WO2002062833A2 (en) | 2002-08-15 |
CN1491232A (zh) | 2004-04-21 |
HUP0402071A2 (hu) | 2005-01-28 |
BR0207018A (pt) | 2004-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA03008961A (es) | Composicion de vacuna. | |
ZA200208561B (en) | Hydraulischer druckverstarker. | |
MXPA01009037A (es) | I-bet. | |
MXPA03007915A (es) | Vacuna. | |
HK1050549A1 (en) | Heater. | |
MXPA03007693A (es) | Composicion para la piel. | |
MXPA03006989A (es) | Leptina modificada con inmunogenicidad reducida. | |
MXPA03008139A (es) | Fluoralcoxifenilsulfonilureas sustituidas. | |
HK1049770A1 (en) | Fan. | |
EG23378A (en) | Composition. | |
MXPA03008394A (es) | Derivados de biuretano. | |
MXPA03008077A (es) | Composicion humedecedora para la piel.. | |
MXPA03007625A (es) | Trombopoyetina modificada con inmunogenicidad reducida. | |
HK1059781A1 (en) | New phenylpiperazines. | |
MXPA03007888A (es) | Compuestos para tratamiento y prevencion de ulcera gastrica inducida por medicamentos. | |
HK1060608A1 (en) | Latch. | |
MXPA03008402A (es) | Insulina modificada con inmunogenicidad reducida. | |
AP2001000098S (en) | Marimbira. | |
MXPA01005710A (es) | Losa-cimbra. | |
MXPA01005709A (es) | Panel-cimbra. | |
MXPA03008086A (es) | Protamina modificada con inmunogenicidad reducida. | |
ZA200108391B (en) | Prop. | |
ZA200206772B (en) | Prop. | |
GB0116210D0 (en) | P.c.o | |
GB0112516D0 (en) | V.i.s.c |